Weebit Nano (ASX:WBT) Q3 shows the royalty model taking shape
Royalty revenue moves closer after Q3
Weebit Nano is one of our favourite stocks and…
- ASX: AFP
AFT Pharmaceuticals Ltd
Share Price and News
ASX BIG FOUR - LIVE SNAPSHOT
SELL
Whitehaven Coal
(ASX:WHC)
Paul Flynn
01/03/2026
$8.7m
BUY
Elixir Energy
(ASX:EXR)
Featured
SELL
Aspen Group
(ASX:APZ)
David Dixon
03/03/2026
$11.4m
BUY
Lovisa
(ASX:LOV)
Brett Blundy
04/03/2026
$6.8m
— Copmany Overview
Overview of AFT Pharmaceuticals (ASX:AFP)
AFT Pharmaceuticals Ltd (ASX: AFP) is a leading Australian-based pharmaceutical company focused on the development, marketing, and distribution of prescription and over-the-counter medicines. The company operates globally, with products reaching markets in Australia, New Zealand, and several international territories. It made $195.4m in FY24, representing a CAGR growth of 18% in 5 years. What sets AFT apart in the industry is its ability to launch and manage a diverse portfolio of products. The company has successfully marketed a range of pharmaceuticals and consumer health products, with a strong focus on quality and patient well-being. Its expansion into both local and international markets has solidified its position as a significant player in the sector. The company’s flagship medicine is Maxigesic. Maxigesic is a pain-killing drug that combines two popular OTC analgesics, paracetamol and ibuprofen, into a unique patented formulation. It is licensed in over 100 countries all up, in tablet, IV and oral (i.e. drink) forms, for the treatment of mild to moderate pain experienced post-operations.
AFT Pharmaceuticals' Company History
AFT Pharmaceuticals was founded in 1997 by Dr Hartley Atkinson, a pharmaceutical entrepreneur. It began as a small local business that imported and distributed other company’s medicines. The Atkinsons are still involved with the business and own a majority stake in it. In 2009, the company commercially launched Maxigesic, which is its flagship medicine, developed in-house through R&D. The company is best known for Maxigesic, but also in-licenses and distributes over 100 other pharmaceutical products in pain relief, eyecare, allergy relief, digestive health and skin care in dozens of countries across the world. The company went public in 2015, listing on the Australian Stock Exchange (ASX) under the ticker symbol AFP. Since then, AFT has expanded its presence in international markets, with a particular focus on the Asia-Pacific region. The company has also made significant strides in establishing a strong position in the United States market, a key growth driver for its future.
- Free Report
Get Our Full ASX Stock Analysis Report
Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.
— Forward View
Future Outlook of AFT Pharmaceuticals (ASX: AFP)
Looking ahead, AFT Pharmaceuticals is poised for growth, with strong revenue and earnings forecasts, bolstered by its international expansion and a robust pipeline of new products. It is planning to reach $300m in rolling annual revenue by the end of FY27 – nearly double FY24 levels. For FY26, it has told investors to expect a NZ$20-24m profit. The company has made significant progress in enhancing its manufacturing capacity, which will help meet the growing demand for its products in global markets. In addition, AFT’s focus on expanding its portfolio with new and innovative treatments, such as over-the-counter pain relief and sleep aids, should support its long-term growth. Sector trends point toward a growing demand for pharmaceuticals as the global population ages, with increasing incidences of chronic conditions. This trend bodes well for AFT’s future, particularly in international markets, where demand for quality healthcare products is rising. Additionally, AFT’s strategic partnerships and acquisitions continue to expand its market reach and product offerings. Despite these growth prospects, AFT Pharmaceuticals faces challenges, including market competition, regulatory hurdles, and the impact of economic fluctuations. And of course, the failure to reach the $300m rolling revenue goal for any (or all) of the aforementioned reasons is a risk in and of itself, for investors dislike it when companies miss projected estimates. However, the company’s proactive approach to innovation and market diversification positions it well for continued success.
— Our Assessment
Is AFT Pharmaceuticals a Good Stock to Buy?
Several factors make AFT potentially attractive for investors. First, it operates in the pharmaceutical and healthcare sector, which tends to be more defensive than many other industries. Demand for medicines generally remains stable even during economic downturns. Second, the company has intellectual property and branded products, particularly Maxigesic, which is being rolled out globally through partnerships and licensing agreements. This gives AFT a scalable revenue model if international uptake continues. Third, the business has been successfully expanding internationally, reducing reliance on its core Australian and New Zealand markets. However, there are also risks. AFT is still a small-cap pharma company, meaning earnings can be volatile due to R&D spending, regulatory approvals and product launch timing. Profit margins also fluctuate depending on licensing income and development investments. Competition in pharmaceuticals is intense, and the company must continue developing new products to sustain growth. All things considered, AFT Pharmaceuticals could appeal to investors looking for a high-growth healthcare small cap with global expansion potential. Its strong revenue growth and pipeline provide upside, but the stock carries higher risk and earnings volatility compared with large pharmaceutical companies. For long-term investors comfortable with small-cap healthcare risk, AFT may represent an emerging growth story rather than a stable income investment.
— Our Stock Analysis
Related Articles
Nanoveu (ASX:NVU) 16nm chip enters TSMC fabrication, A$7.5m raise funds the validation push
Design completion is not the milestone that moves a semiconductor company from interesting to credible.…
DorsaVi (ASX:DVL) Ultra Edge AI Could Unlock a Re-Rate Toward Our Base Valuation
DorsaVi (ASX:DVL) holds two IP acquisitions in ReRAM and neuromorphic AI. We value the stock…
Celestica (NYSE:CLS) The AI Infrastructure Winner No One Wanted This Quarter
Celestica (NYSE:CLS) posted 53% revenue growth and a record 8% margin in Q1 2026, but…
The 50% CGT discount on shares: Here’s how it works, and if it is under threat
The 50% CGT discount on shares is one of the key mechanisms that helps investors…
Apple’s New Era: What the Tim Cook to John Ternus Transition Means for the World’s Most...
Apple (NASDAQ: AAPL) has confirmed that Tim Cook will step down as chief executive officer…
— Faq
Frequently Asked Questions
What is the dividend yield of AFT Pharmaceuticals (ASX: AFP)?
AFT Pharmaceuticals’ dividend yield is less than 1% as it has only paid dividends twice (at the end of FY23 and FY24) and it was just 1c per share – both representing yields of 0.29% and 0.54% respectively. Its policy is to pay 20-30% of (normalised) NPAT.
How does AFT Pharmaceuticals (ASX: AFP) compare to its peers?
AFT Pharmaceuticals is well-positioned in comparison to its peers in the Australian pharmaceutical sector. It stands out due to its diverse product portfolio and strong international market presence, which offers resilience against market fluctuations.
What are the risks of investing in AFT Pharmaceuticals (ASX: AFP)?
While AFT Pharmaceuticals shows strong growth potential, risks include regulatory changes, market competition, and economic volatility. Additionally, the company is exposed to international market dynamics, which could affect its operations.
Does AFT Pharmaceuticals (ASX: AFP) have any international expansion plans?
Yes, AFT Pharmaceuticals has a clear focus on expanding its reach in international markets, especially in the U.S. and Asia-Pacific regions. This global expansion strategy is integral to its long-term growth plan.
Is AFT Pharmaceuticals (ASX: AFP) a stable long-term investment?
AFT Pharmaceuticals presents a relatively stable long-term investment due to its consistent revenue growth, strong market position, and commitment to innovation. However, as with any pharmaceutical company, investors should consider sector-specific risks when evaluating long-term stability.
Stay Sharp on the ASX
Weekly research. Independent analysis. No noise.
Free forever · Unsubscribe anytime
